| |
|
|
|
|
|
Wallac DELFIA® and AutoDELFIA® PSA kits are for the quantitative determination of Prostate Specific Antigen in human serum.
ProStatus™ PSA EQM Kits are specifically designed for the follow-up of patients who have been diagnosed as having prostate cancer.
The ProStatus PSA Free/Total kits are for the simultaneous quantitative determination of the total amount of prostate spcific antigen and the amount of free prostate specific antigen (uncomplexed PSA) in serum.
These solid-phase, two-site fluoroimmunonometric assays are based on the direct sandwich technique in which two monoclonal antib
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
allac DELFIA® and AutoDELFIA® PSA kits are for the quantitative determination of Prostate Specific Antigen in human serum.
ProStatus™ PSA EQM Kits are specifically designed for the follow-up of patients who have been diagnosed as having prostate cancer.
The ProStatus PSA Free/Total kits are for the simultaneous quantitative determination of the total amount of prostate spcific antigen and the amount of free prostate specific antigen (uncomplexed PSA) in serum.
These solid-phase, two-site fluoroimmunonometric assays are based on the direct sandwich technique in which two monoclonal antibo
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
Wallac DELFIA® and AutoDELFIA® PSA kits are for the quantitative determination of Prostate Specific Antigen in human serum.
ProStatus™ PSA EQM Kits are specifically designed for the follow-up of patients who have been diagnosed as having prostate cancer.
The ProStatus PSA Free/Total kits are for the simultaneous quantitative determination of the total amount of prostate spcific antigen and the amount of free prostate specific antigen (uncomplexed PSA) in serum.
These solid-phase, two-site fluoroimmunonometric assays are based on the direct sandwich technique in which two monoclonal antib
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
Prostate cancer is the most frequent type of cancer found in the man and the second cause of death due to the cancer in
man, Until recently, digital rectal examination was the most accepted diagnostic modality for early stage of prostate
cancer but the measurement of serum PSA has become the most accepted test to indicate men who are at risk of having
prostate cancer and who should be examined by other tests. Other biochemical markers used in this context (PAP, total
alkaline phosphatase, carcinoembryonic antigen, etc,), are not as specific for prostate cancer. In 1979, Wang et al isolated
a s
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
Materials provided with the kits:
• Rabbit anti-PSA coated microtiter plate with 96 wells.
• Zero Buffer, 7 ml.
• Reference standard containing 0, 2, 4, 15, 60, and 120 ng/ml PSA, lyophilized. 1 set.
• Enzyme Conjugate Reagent, 12 ml.
• TMB Reagent (one step), 11 ml.
• Stop Solution (1N HCl), 11 ml.
Materials required but not provided:
• Precision pipettes: 50 μl, 100 μl and 1.0 ml.
• Disposable pipette tips.
• Distilled water.
• Vortex mixer or equivalent.
• Absorbent paper or paper towel.
• Graph paper.
• A microtiter plate reader with a bandwidth of 10 nm or less and an optical density rang
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
PRINCIPLE OF THE TEST
The principle of this chemiluminescence immunoassay (CLIA) test follows a typical one-step capture or ‘sandwich’ type
assay. The assay makes use of two highly specific monoclonal antibodies: A monoclonal antibody specific for total PSA
is immobilized onto the microwell plate and another monoclonal antibody specific for a different region of PSA is
conjugated to horse radish peroxidase (HRP). Total PSA from the sample and standards are allowed to bind to the plate,
washed, and subsequently incubated with the HRP conjugate. After a second washing step, the luminescence subs
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
Human Prostate Specific Antigen (PSA) is a 33 kD serine proteinase which, in human serum, is predominantly bound to alpha 1-antichymotrypsin (PSA-ACT) and alpha 2-macroglobulin (PSA-AMG). Trace amounts of alpha 1-antitrypsin and inter-alpha trypsin inhibitor bound to PSA can also be found. Any remaining PSA is in the free form (f-PSA).1-3 Current methods of screening men for prostate cancer utilize the detection of the major PSA-ACT form. Levels of 4.0 ng/ml or higher are strong indicators of the possibility of prostatic cancer.4 However, elevated serum PSA levels have also been attributed to
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
This First Diagnostic PSA Gold Test is a rapid direct binding test for the detection of Prostate Specific Antigen (PSA) in serum as an aid in the diagnosis of prostate cancer. The test is based on the principle of sandwich immunoassay for determination of PSA in serum. Monoclonal and polyclonal antibodies are employed to identify PSA specifically. This one step test is very sensitive and only takes about 10 -20 minutes.
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
The CALBIOTECH INC (CBI), f-PSA ELISA kit is used for the quantitative measurement of f-PSA in human
serum or plasma. Human Prostate Specific Antigen (PSA) is a 33 kD serine proteinase which, in human serum, is
predominantly bound to alpha 1-antichymotrypsin (PSA-ACT) and alpha 2-macroglobulin (PSAAMG).
Trace amounts of alpha 1-antitrypsin and inter-alpha trypsin inhibitor bound to PSA can also b
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|
|
|
|
|
Human Prostate Specific Antigen (PSA) is a 33 kD serine
proteinase which, in human serum, is predominantly bound to alpha
1-antichymotrypsin (PSA-ACT) and alpha 2-macroglobulin (PSAAMG).
Trace amounts of alpha 1-antitrypsin and inter-alpha trypsin
inhibitor bound to PSA can also be found. Any remaining PSA is in
the free form (f-PSA).1-3 Current methods of screening men for
prostate cancer utilize the detection of the major PSA-ACT form.
Levels of 4.0 ng/ml or higher are strong indicators of the possibility
of prostatic cancer.4 However, elevated serum PSA levels have
also been attributed to b
|
Company:
Date:
December 11, 2008
|
|
|
|
|
|